Lipoproteins and coagulation

Perfusion

Volumn 12, Issue 6, 1997, Pages 349-356

  Basile Borgia, Annette ^a,b   Abel, John H ^b  

^a EASTON HOSPITAL   (United States)

^b LEHIGH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; LIPOPROTEIN;

CARDIOPULMONARY BYPASS; CELL INTERACTION; FIBRINOLYSIS; HEART DISEASE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEMOSTASIS; HUMAN; HYPERLIPIDEMIA; PRIORITY JOURNAL; REVIEW; THROMBOGENESIS; VASCULAR ENDOTHELIUM;

EID: 0030859665     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/026765919701200603     Document Type: Review

References (37)

1. Campbell FW, Jobes DR, Ellison N. Coagulation management during and after cardiopulmonary bypass. In: Hensley FA, Martin DE eds. A practical approach to cardiac anesthesia, 2nd edition. Boston, MA: Little, Brown, 1995: 434-63.
2. Chen RH, Frazier OH, Colley DA. Antifibrinolytic therapy in cardiac surgery Tex Heart Inst J 1995; 22: 211-15.
3. Ferraris VA, Ferraris SP. Limiting excessive postoperative blood transfusion after cardiac procedures: a review. Tex Heart Inst J 1995; 22: 216-30.
4. Penta de Peppo A, Pierri MD, Scafuri A et al. Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery: prospective trial of three antifibrinolytic drugs. Tex Heart Inst J 1995; 22: 231-36.
5. Hunt BJ. The relation between abnormal hemostatic function and the progression of coronary disease. Curr Opin Cardiol 1990; 5: 758-65.
6. Hamsten A. Coagulation factors and hyperlipidemia. Curr Opin Lipidol 1991; 2: 266-71.
7. Nachman RL. Thrombosis and atherogenesis: molecular connections. Blood 1992; 79: 1897-906.
8. Fuster V. Elucidation of the role of plaque instability and rupture in acute coronary events. Am J Cardiol 1995; 76: 24C-33C.
9. Navab M, Folgelman AM, Berliner JA et al. Pathogenesis of atherosclerosis. Am J Cardiol 1995; 76: 18C-24C.
10. Mitropoulos KA. Lipid-thrombosis interface. Br Med Bull 1994; 50: 813-32.
11. Genest J, Cohn JS. Clustering of cardiovascular risk factors: targeting high-risk individuals. Am J Cardiol 1995; 76: 8A-20A.
12. Kinlay S, Selwyn AP, Delagrange D, Creager MA, Libby P, Ganz P. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points. Curr Opin Lipidol 1996; 7: 389-97.
13. Schmieder RE, Schobel HP. Is endothelial dysfunction reversible? Am J Cardiol 1995; 76: 117A-21A.
14. Kottke-Marchant K. Laboratory diagnosis of hemorrhagic and thrombotic disorders. Hematol Oncol Clin North Am 1994; 8: 809-53.
15. Sala N, Fontcuberta J, Rutllant ML. New biological concepts on coagulation inhibitors. Int Care Med 1993; 19: S3-S7.
16. Willerson JT. Conversion from chronic to acute coronary heart disease syndromes. Tex Heart Inst J 1995; 22: 13-19.
17. Warkentin TE. Hemostasis and atherosclerosis. Can J Cardiol; 11: 29C-34C.
18. Juhan-Vague I. Hemostasis risk factors in cardiovascular disease [Abstract]. XII international symposium on drugs affecting lipid metabolism. Houston, TX, 1995.
19. Luchtman-Jones L, Broze GC. The current status of coagulation. Ann Med 1995; 27: 47-52.
20. Guyton AC. Textbook of medical physiology, 6th edition. Philadelphia, PA: WB Saunders, 1981: 876.
21. Dorland's illustrated medical dictionary, 25th edition. Philadelphia, PA: WB Saunders, 1974.
22. Ballantyne CM, Chan L, Guevara J et al. Recent advances in lipoprotein and atherosclerosis research at Baylor College of Medicine. Tex Heart Inst J 1994; 21: 48-55.
23. Edelberg J, Pizzo SV. Lipoprotein(a) regulates plasmin generation and inhibition. Chem Phys Lipids 1994; 67-68: 363-68.
24. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989; 339: 303-305.
25. Rabbini LE, Loscalzo J. Recent observations on the role of hemostatic determinants in the development of the atherothrombotic plaque. Atheroscl 1995; 105: 1-7.
26. Johansson J, Egberg N, Johnsson H, Carlson LA. Serum lipoproteins and hemostatic function in intermittent claudication. Arterioscler Thromb 1993; 13: 1441-48.
27. Holme I. Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol 1995; 76: 10C-17C.
28. Gotto AM. Lipid risk factors and the regression of atherosclerosis. Am J Cardiol 1995; 76: 3A-7A.
29. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993; 44: 121-31.
30. Daae Ln, Kierulf P, Lanndaas S, Urdal P. Cardiovascular risk factors: interactive effects of lipids, coagulation and fibrinolysis. Scand J Clin Lab Invest 1993; 53: 19-27.
31. Tikkanen MJ. Statins: within-group comparisons, statin escape and combination therapy. Curr Opin Lipidol 1996; 7: 385-88.
32. Christenson JT, Gras PA, Grosclaude A et al. Reactive thrombocytosis following coronary artery bypass surgery: a possible link to a lipid dysfunction. J Cardiovasc Surg 1996; 37: 491-98.
33. Boyle EM, Verrier ED, Spiess BD. Endothelial cell injury in cardiovascular surgery: the procoagulant response. Ann Thorac Surg 1996; 62: 1549-57.
34. Gordon BR, Saal SD. Current status of low density lipoprotein-apheresis for the therapy of severe hyperlipidemia. Curr Opin Lipidol 1996; 7: 381-84.
35. Daida H, Young JL, Yokoi H et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein(a) levels with low-density lipoprotein apheresis. Am J Cardiol 1994; 73: 1037-40.
36. Hamsten A, Karpe F, Bavenholm P, Silveira A. Interactions amongst insulin, lipoproteins and hemostatic function relevant to coronary heart disease. J Int Med 1994; 236: 75-88.
37. Gibbons GH, Dzau VJ. Molecular therapies for vascular diseases. Science 1996; 272: 689-93.